On August 21, 2026, Hang Seng Indexes Company unveiled the results of its quarterly index review as of June 30, 2026, with Tennor Therap-B (06872) being added to the Hang Seng Composite Index. The adjustment will take effect after the market close on Friday, September 4, and will be implemented starting Monday, September 7, at which point the Shanghai and Shenzhen stock exchanges will correspondingly update the eligible securities list for the Stock Connect program.

Tennor Therap-B (06872) is poised to become a candidate for inclusion in the Stock Connect southbound trading channel, having satisfied a series of criteria including market capitalization and liquidity requirements. According to publicly available information, the company is dedicated to the research and development of innovative drugs targeting bacterial infections and diseases associated with bacterial metabolism.

Currently, Tennor Therap-B has established a pipeline comprising seven drug candidates, with a strategic focus on indications that lack or have limited existing treatment options. The company's lead product, Rifasutenizol (TNP-2198), stands as the world's first and only new molecular entity candidate drug targeting Helicobacter pylori infection since its discovery in 1982. The company submitted a new drug application to China's National Medical Products Administration in August 2025, with expectations for regulatory approval by the end of 2026.

Another core product, Rifaquinitone (TNP-2092 injection), targets implant-associated bacterial infections. According to the prospectus, this product represents the world's first new molecular entity candidate drug expected to demonstrate efficacy against biofilm infections at clinically achievable doses. The company has already submitted Phase III multi-domain clinical trial protocols to both the National Medical Products Administration and the U.S. Food and Drug Administration.